Delek US (DK) director sells 29,372 shares under 10b5-1 trading plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Delek US Holdings director Zohar Shlomo reported open‑market sales of company common stock under a pre‑arranged trading plan. On March 4–5, 2026, he sold a total of 29,372 shares of Delek US Holdings common stock in several transactions at prices between $43.00 and $45.50 per share. Following these sales, he directly owned 18,989 shares of the company’s common stock. The filing notes that these transactions were made pursuant to a Rule 10b5‑1 trading plan adopted on November 13, 2025, intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c).
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 29,372 shares ($1,303,383)
Net Sell
4 txns
Insider
Zohar Shlomo
Role
Director
Sold
29,372 shs ($1.30M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,343 | $44.00 | $323K |
| Sale | Common Stock | 7,343 | $45.00 | $330K |
| Sale | Common Stock | 7,343 | $45.50 | $334K |
| Sale | Common Stock | 7,343 | $43.00 | $316K |
Holdings After Transaction:
Common Stock — 33,675 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Delek US (DK) director Zohar Shlomo report in this Form 4?
Director Zohar Shlomo reported selling Delek US common stock in open-market transactions. The Form 4 discloses multiple sales made on March 4–5, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025.
What type of transactions did Delek US (DK) director Zohar Shlomo report?
He reported open-market sales of common stock, coded “S” on Form 4. All four transactions involved non-derivative common shares and are described as sales in the open market or private transactions, with direct ownership reported after each sale.